Watery diarrhea, hypokalemia, achlorhydria syndrome in an infant: effect of the long-acting somatostatin analogue SMS 201-995 on the disease and linear growth.
An 8-week-old infant presented with vomiting and failure to thrive due to small bowel obstruction caused by a diffusely enlarged pancreas. Surgical bypass of the obstruction was followed by secretory diarrhea, hypokalemia, and dehydration. Plasma vasoactive intestinal peptide (VIP) (823pg/ml), pancreatic polypeptide (4,500 pg/ml), and neurotensin (680 pg/ml) concentrations were markedly elevated. No neoplastic process was identified. Therapy with the long-acting somatostatin analogue SMS 201-995 was followed by decline in VIP concentrations (900 to 200-300 pg/ml), decrease in stool frequency, and normalization of serum electrolytes. During 12 months of somatostatin analogue therapy, length and weight progressed along the 3rd percentile on the Tanner growth chart.
D000126:Achlorhydria / Q000188:drug therapy* / Q000378:metabolism; D001827:Body Height / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002675:Child, Preschool; D003968:Diarrhea, Infantile / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D007008:Hypokalemia / Q000188:drug therapy* / Q000378:metabolism; D007223:Infant; D015282:Octreotide; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D013577:Syndrome
D013004:Somatostatin; D015282:Octreotide